Cargando…
Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in a refugee camp, Dagahaley, Kenya
BACKGROUND: Camps of forcibly displaced populations are considered to be at risk of large COVID-19 outbreaks. Low screening rates and limited surveillance led us to conduct a study in Dagahaley camp, located in the Dadaab refugee complex in Kenya to estimate SARS-COV-2 seroprevalence and, mortality...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683031/ https://www.ncbi.nlm.nih.gov/pubmed/34919545 http://dx.doi.org/10.1371/journal.pone.0260989 |
_version_ | 1784617331238895616 |
---|---|
author | Gignoux, Etienne Athanassiadis, Frida Garat Yarrow, Ahmed Jimale, Abdullahi Mubuto, Nicole Déglise, Carole Onsongo Mosoti, Denis Azman, Andrew S. Mwau, Matilu Luquero, Francisco Ciglenecki, Iza |
author_facet | Gignoux, Etienne Athanassiadis, Frida Garat Yarrow, Ahmed Jimale, Abdullahi Mubuto, Nicole Déglise, Carole Onsongo Mosoti, Denis Azman, Andrew S. Mwau, Matilu Luquero, Francisco Ciglenecki, Iza |
author_sort | Gignoux, Etienne |
collection | PubMed |
description | BACKGROUND: Camps of forcibly displaced populations are considered to be at risk of large COVID-19 outbreaks. Low screening rates and limited surveillance led us to conduct a study in Dagahaley camp, located in the Dadaab refugee complex in Kenya to estimate SARS-COV-2 seroprevalence and, mortality and to identify changes in access to care during the pandemic. METHODS: To estimate seroprevalence, a cross-sectional survey was conducted among a sample of individuals (n = 587) seeking care at the two main health centres and among all household members (n = 619) of community health workers and traditional birth attendants working in the camp. A rapid immunologic assay was used (BIOSYNEX® COVID‐19 BSS [IgG/IgM]) and adjusted for test performance and mismatch between the sampled population and that of the general camp population. To estimate mortality, all households (n = 12860) were exhaustively interviewed in the camp about deaths occurring from January 2019 through March 2021. RESULTS: In total 1206 participants were included in the seroprevalence study, 8% (95% CI: 6.6%-9.7%) had a positive serologic test. After adjusting for test performance and standardizing on age, a seroprevalence of 5.8% was estimated (95% CI: 1.6%-8.4%). The mortality rate for 10,000 persons per day was 0.05 (95% CI 0.05–0.06) prior to the pandemic and 0.07 (95% CI 0.06–0.08) during the pandemic, representing a significant 42% increase (p<0.001). Médecins Sans Frontières health centre consultations and hospital admissions decreased by 38% and 37% respectively. CONCLUSION: The number of infected people was estimated 67 times higher than the number of reported cases. Participants aged 50 years or more were among the most affected. The mortality survey shows an increase in the mortality rate during the pandemic compared to before the pandemic. A decline in attendance at health facilities was observed and sustained despite the easing of restrictions. |
format | Online Article Text |
id | pubmed-8683031 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-86830312021-12-18 Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in a refugee camp, Dagahaley, Kenya Gignoux, Etienne Athanassiadis, Frida Garat Yarrow, Ahmed Jimale, Abdullahi Mubuto, Nicole Déglise, Carole Onsongo Mosoti, Denis Azman, Andrew S. Mwau, Matilu Luquero, Francisco Ciglenecki, Iza PLoS One Research Article BACKGROUND: Camps of forcibly displaced populations are considered to be at risk of large COVID-19 outbreaks. Low screening rates and limited surveillance led us to conduct a study in Dagahaley camp, located in the Dadaab refugee complex in Kenya to estimate SARS-COV-2 seroprevalence and, mortality and to identify changes in access to care during the pandemic. METHODS: To estimate seroprevalence, a cross-sectional survey was conducted among a sample of individuals (n = 587) seeking care at the two main health centres and among all household members (n = 619) of community health workers and traditional birth attendants working in the camp. A rapid immunologic assay was used (BIOSYNEX® COVID‐19 BSS [IgG/IgM]) and adjusted for test performance and mismatch between the sampled population and that of the general camp population. To estimate mortality, all households (n = 12860) were exhaustively interviewed in the camp about deaths occurring from January 2019 through March 2021. RESULTS: In total 1206 participants were included in the seroprevalence study, 8% (95% CI: 6.6%-9.7%) had a positive serologic test. After adjusting for test performance and standardizing on age, a seroprevalence of 5.8% was estimated (95% CI: 1.6%-8.4%). The mortality rate for 10,000 persons per day was 0.05 (95% CI 0.05–0.06) prior to the pandemic and 0.07 (95% CI 0.06–0.08) during the pandemic, representing a significant 42% increase (p<0.001). Médecins Sans Frontières health centre consultations and hospital admissions decreased by 38% and 37% respectively. CONCLUSION: The number of infected people was estimated 67 times higher than the number of reported cases. Participants aged 50 years or more were among the most affected. The mortality survey shows an increase in the mortality rate during the pandemic compared to before the pandemic. A decline in attendance at health facilities was observed and sustained despite the easing of restrictions. Public Library of Science 2021-12-17 /pmc/articles/PMC8683031/ /pubmed/34919545 http://dx.doi.org/10.1371/journal.pone.0260989 Text en © 2021 Gignoux et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Gignoux, Etienne Athanassiadis, Frida Garat Yarrow, Ahmed Jimale, Abdullahi Mubuto, Nicole Déglise, Carole Onsongo Mosoti, Denis Azman, Andrew S. Mwau, Matilu Luquero, Francisco Ciglenecki, Iza Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in a refugee camp, Dagahaley, Kenya |
title | Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in a refugee camp, Dagahaley, Kenya |
title_full | Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in a refugee camp, Dagahaley, Kenya |
title_fullStr | Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in a refugee camp, Dagahaley, Kenya |
title_full_unstemmed | Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in a refugee camp, Dagahaley, Kenya |
title_short | Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in a refugee camp, Dagahaley, Kenya |
title_sort | seroprevalence of sars-cov-2 antibodies and retrospective mortality in a refugee camp, dagahaley, kenya |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683031/ https://www.ncbi.nlm.nih.gov/pubmed/34919545 http://dx.doi.org/10.1371/journal.pone.0260989 |
work_keys_str_mv | AT gignouxetienne seroprevalenceofsarscov2antibodiesandretrospectivemortalityinarefugeecampdagahaleykenya AT athanassiadisfrida seroprevalenceofsarscov2antibodiesandretrospectivemortalityinarefugeecampdagahaleykenya AT garatyarrowahmed seroprevalenceofsarscov2antibodiesandretrospectivemortalityinarefugeecampdagahaleykenya AT jimaleabdullahi seroprevalenceofsarscov2antibodiesandretrospectivemortalityinarefugeecampdagahaleykenya AT mubutonicole seroprevalenceofsarscov2antibodiesandretrospectivemortalityinarefugeecampdagahaleykenya AT deglisecarole seroprevalenceofsarscov2antibodiesandretrospectivemortalityinarefugeecampdagahaleykenya AT onsongomosotidenis seroprevalenceofsarscov2antibodiesandretrospectivemortalityinarefugeecampdagahaleykenya AT azmanandrews seroprevalenceofsarscov2antibodiesandretrospectivemortalityinarefugeecampdagahaleykenya AT mwaumatilu seroprevalenceofsarscov2antibodiesandretrospectivemortalityinarefugeecampdagahaleykenya AT luquerofrancisco seroprevalenceofsarscov2antibodiesandretrospectivemortalityinarefugeecampdagahaleykenya AT cigleneckiiza seroprevalenceofsarscov2antibodiesandretrospectivemortalityinarefugeecampdagahaleykenya |